CureVac’s seasonal flu vaccine boosted antibody titers in influenza A strains but it missed the mark in influenza B in a Phase 2 trial.
The mRNA biotech, which is developing the vaccine with GSK, on Thursday announced the interim data from the ongoing trial. Its stock $CVAC was up about 1.5%, trading at $2.95.
CureVac said the titers generated by its vaccine candidate exceeded the titers from the comparison vaccine against influenza A strains across all dose levels.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.